CoronaVac reduces mortality by 97%: Uruguayan study –

0
7
CoronaVac reduces mortality by 97%: Uruguayan study – fr


Montevideo (AFP)

The CoronaVac vaccine reduces coronavirus mortality by 97%, according to the first results of the vaccination campaign in Uruguay, which relies heavily on the Chinese vaccine.

In people who had received two doses, this reduced coronavirus infection by 57% and intensive care admissions by 95%, according to a report from the South American nation’s Department of Health.

Compared to other vaccines used, there has been little scientific publication on the effectiveness of CoronaVac, produced by the Chinese company Sinovac, and widely divergent results.

Coronavac is nonetheless widely used in China and around 20 other countries.

Chile reported last month that the first results of its vaccination campaign showed CoronaVac to be 67% effective in preventing symptoms of Covid-19 and 80% effective in preventing death.

Results from trials with CoronaVac in Brazil showed around 50 percent effectiveness in preventing symptomatic infections, while Turkish data indicated that it was over 80 percent effective.

Uruguay, which started vaccinating on March 1, has used CoronaVac more than 80% of the time.

He reserved the Pfizer-BioNTech jab for the elderly, health workers and people with other illnesses.

– Preliminary –

The results are based on the results two weeks after two injections were given to some 862,000 people – over 712,000 who received CoronaVac and almost 150,000 Pfizer.

The results showed that Pfizer’s shot was 75 percent effective in preventing infections, 99 percent in preventing illnesses requiring intensive care admission, and 80 percent in preventing death.

Results with the two vaccines are not directly comparable, as Pfizer beneficiaries in Uruguay fell into high-risk categories, the ministry said.

Other studies have attached much better results to Pfizer.

The largest real-world Pfizer study to date, in Israel, said this month it offers over 95% protection against Covid-19.

CoronaVac is a traditional type of vaccine, using an inactivated virus to trigger immunity, while Pfizer uses messenger RNA technology.

Uruguay, with a population of 3.5 million, has administered at least one dose of vaccine to 45.8% of the target population and two doses to 28.29% by May 25, which places it third in the Americas behind Chile and the United States.

The country has never had a lockdown and had relatively few cases in the early months of the outbreak, but in recent weeks the world has dominated the number of daily deaths per capita.

The ministry said the results are preliminary and should be interpreted with caution as some data has yet to be processed.

LEAVE A REPLY

Please enter your comment!
Please enter your name here